Clinical Trial

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
In this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent vulvovaginal candidiasis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-19; most recent amendment 2026-03-02.
Status change: Recruiting → Active, Not Recruiting 2026-03-02
Trial Details
NCT Number NCT06190509
Lead Sponsor LimmaTech Biologics AG
Collaborators: GlaxoSmithKline
Conditions Recurrent Vulvovaginal Candidiasis
Enrollment 251 participants
Start Date 2023-12-06
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-04